Lipopolysaccharide-activated alveolar macrophages having cytotoxicity toward lung tumor cells through cell-to-cell binding-dependent mechanism

Anticancer Research

Volumn 30, Issue 8, 2010, Pages 3159-3165

  Taniguchi, Hiroaki ^a   Shimada, Yasuteru ^a   Sawachi, Keiichi ^a   Hirota, Keiji ^a   Inagawa, Hiroyuki ^a,b   Kohchi, Chie ^a,b   Soma, Gen Ichiro ^a,b,c   Makino, Kimiko ^a   Terada, Hiroshi ^a  

^a TOKYO UNIVERSITY OF SCIENCE   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

^c TOKUSHIMA BUNRI UNIVERSITY   (Japan)

Author keywords

Alveolar macrophage; Cell to cell contact; Drug delivery system; LPS; Lung tumor

Indexed keywords

CYTOSTATIC AGENT; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA; INTERLEUKIN 1;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL AGGREGATION; CELL GROWTH; CELL INTERACTION; CELL VIABILITY; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG UPTAKE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; LUNG ALVEOLUS MACROPHAGE; LUNG TUMOR; MACROPHAGE ACTIVATION; MACROPHAGE MIGRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR CELL; ADENOCARCINOMA; BIOSYNTHESIS; CELL FUSION; COCULTURE; DRUG EFFECT; IMMUNOLOGY; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; CELL FUSION; CELL LINE, TUMOR; COCULTURE TECHNIQUES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERLEUKIN-1; LIPOPOLYSACCHARIDES; LUNG NEOPLASMS; MACROPHAGE ACTIVATION; MACROPHAGES, ALVEOLAR; NITRIC OXIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77957333775     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
2. Spiro SG and Porter JC: Lung cancer-where are we today? Current advances in staging and nonsurgical treatment. Am J Respir Crit Care Med 166: 1166-1196, 2002.
3. Stewart DJ: Update on the role of topotecan in the treatment of non-small cell lung cancer. Oncologist 9: 43-52, 2004.
4. Auger MJ and Ross JA: The Macrophage. Oxford: Oxford University Press, 2002.
5. Gordon S: Alternative activation of macrophages. Nat Rev Immunol 3: 23-35, 2003.
6. Mantovani A, Sozzani S, Locati M, Allavena P and Sica A: Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549-555, 2002. (Pubitemid 35223554)
7. Umemura N, Saio M, Suwa T, Kitoh Y, Bai J, Nonaka K, Ouyang GF, Okada M, Balazs M, Adany R, Shibata T and Takami T: Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1-and M2-type characteristics. J Leukoc Biol 83: 1136-1144, 2008.
8. Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, Robinson SC and Balkwill FR: 'Re-educating' tumor-associated macrophages by targeting NF-kappaB. J Exp Med 205: 1261-1268, 2008.
9. Fong CH, Bebien M, Didierlaurent A, Nebauer R, Hussell T, Broide D, Karin M and Lawrence T: An antiinflammatory role for IKK-beta through the inhibition of 'classical' macrophage activation. J Exp Med 205: 1269-1276, 2008.
10. -/- mice. Anticancer Res 29: 5095-5101, 2009.
11. Kadowaki T, Yasui Y, Takahashi Y, Kohchi C, Soma G and Inagawa H: Comparative immunological analysis of innate immunity activation after oral administration of wheat fermented extract to teleost fish. Anticancer Res 29: 4871-4877, 2009.
12. FeLs AO and Cohn ZA: The alveolar macrophage. J Appl Physiol 60: 353-369, 1986.
13. Newman SP and Busse WW: Evolution of dry powder inhaler design, formulation, and performance. Respir Med 96: 293-304, 2002.
14. Sethuraman VV and Hickey AJ: Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug. AAPS PharmSciTech 3: E28, 2002.
15. Hirota K, Hasegawa T, Nakajima T, Inagawa H, Kohchi C, Soma G, Makino K and Terada H: Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis. J Control Release 142: 339-346, 2010.
16. Ding AH, Nathan CF and Stuehr DJ: Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol 141: 2407-2412, 1988.
17. Granger DL, Taintor RR, Boockvar KS and Hibbs JB Jr: Measurement of nitrate and nitrite in biological samples using nitrate reductase and Griess reaction. Methods Enzymol 268: 142-151, 1996.
18. Gordon S, Perry VH, Rabinowitz S, Chung LP and Rosen H: Plasma membrane receptors of the mononuclear phagocyte system. J Cell Sci 9: 1-26, 1988.
19. Kimura S, Sone S, Takahashi K, Uyama T, Ogura T and Monden Y: Antitumour potential of pleural cavity macrophages in lung cancer patients without malignant effusion. Br J Cancer 59: 535-539, 1989. (Pubitemid 19111742)
20. van Horssen R, Ten Hagen TL and Eggermont AM: TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 11: 397-408, 2006.
21. Dinarello CA: Biology of interleukin 1. FASEB J 2: 108-115, 1988.
22. Schmidt HH and Walter U: NO at work. Cell 78: 919-925, 1994.
23. Sveinbjornsson B, Olsen R, Seternes OM and Seljelid R: Macrophage cytotoxicity against murine meth A sarcoma involves nitric oxide-mediated apoptosis. Biochem Biophys Res Commun 223: 643-649, 1996.
24. Beckman JS, Chen J, Crow JP and Ye YZ: Reactions of nitric oxide, superoxide and peroxynitrite with superoxide dismutase in neurodegeneration. Prog Brain Res 103: 371-380, 1994.
25. MacMicking J, Xie QW and Nathan C: Nitric oxide and macrophage function. Annu Rev Immunol 15: 323-350, 1997.